Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide

Biochemical and Biophysical Research Communications

Volumn 412, Issue 4, 2011, Pages 606-611

  Hauptstock, Vera ^a   Kuriakose, Sapuna ^a   Schmidt, Doris ^a   Düster, Robert ^a   Müller, Stefan C ^a   von Ruecker, Alexander ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Depsipeptide; GSTP1; HDAC inhibitor; Histone; Methylation; Prostate cancer

Indexed keywords

DEPSIPEPTIDE; GLUTATHIONE TRANSFERASE P1; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION;

APOPTOSIS; CELL LINE, TUMOR; DEPSIPEPTIDES; DNA METHYLATION; GENE SILENCING; GLUTATHIONE S-TRANSFERASE PI; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 80052610961     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.007     Document Type: Article

References (33)

1. Baylin S., Herman J., Graff J., et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
2. Ellinger J., Bastian P.J., Jurgan T., et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008, 71:161-167.
3. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
4. Majid S., Dar A.A., Shahryari V., et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010, 116:66-76.
5. Singal R., van Wert J., Bashambu M. Cytosine methylation represses Glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 2001, 61:4820-4826.
6. Dobosy J., Roberts J., Fu V., Jarrard D. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 2007, 177:822-831.
7. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
8. Furumai R., Matsuyama A., Kobashi N., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62:4916-4921.
9. Wu L.P., Wang X., Li L., et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell. Biol. 2008, 28:3219-3235.
10. Nakayama M., Bennett C.J., Hicks J.L., et al. Hypermethylation of the human Glutathione S-transferase-{pi} gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 2003, 163:923-933.
11. Stirzaker C., Song J., Davidson B., Clark S.J. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res. 2004, 64:3871-3877.
12. Shang Y., Myer M., Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9:601-610.
13. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 2000, 92:1210-1216.
14. Molife L.R., Attard G., Fong P.C., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 2010, 21:109-113.
15. Lai M., Yang C., Lin T., et al. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urol. Oncol. 2008, 26:182-189.
16. Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103:4636-4643.
17. Blagosklonny M.V., Robey R., Sackett D.L., et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 2002, 1:937-941.
18. Chen G., Li A., Zhao M., et al. Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells. J. Proteome Res. 2008, 7:2733-2742.
19. Okino S.T., Pookot D., Majid S., et al. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol. Carcinog. 2007, 46:839-846.
20. Ellinger J., Kahl P., von der Gathen J., et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.
21. Tachibana M., Sugimoto K., Fukushima T., Shinkai Y. SET domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysine 9 and 27 of histone H3. J. Biol. Chem. 2001, 276:25309-25317.
22. van Leenders G.J., Dukers D., Hessels D., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 2006, 52:455-463.
23. Karanikolas B.D., Figueiredo M.L., Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010, 70:675-688.
24. Fiskus W., Pranpat M., Blasis M., et al. Histone deacetylase inhibitor deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther. 2006, 5:3096-3104.
25. Bommi P.V., Dimri M., Sahasrabuddhe A.A., et al. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010, 9:2663-2673.
26. Jung J.W., Lee S., Seo M.S., et al. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell. Mol. Life Sci. 2010, 67:1165-1176.
27. Hong S., Cho Y.W., Yu L.R., et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl Acad. Sci. USA 2007, 104:18439-18444.
28. Huang P.H., Chen C.H., Chou C.C., et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol. Pharmacol. 2011, 79:97-206.
29. Lin X., Nelson W.G. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res. 2003, 63:498-504.
30. Bakker J., Lin X., Nelson W.G. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 2002, 277:22573-22580.
31. Yoshida M., Horinouchi S., Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 1995, 17:423-430.
32. Fan C., He L., Kapoor A., et al. Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. Biochim. Biophys. Acta 2008, 1782:642-648.
33. Hernández-Muñoz I., Taghavi P., Kuijl C., et al. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol. Cell. Biol. 2005, 25:11047-11058.